Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Celularity Inc

Healthcare US CELUW

0.005USD
0.00(0%)

Last update at 2026-06-23T19:52:00Z

Day Range

0.00410.005
LowHigh

52 Week Range

0.0040.07
LowHigh

Fundamentals

  • Previous Close 0.005
  • Market Cap0.00000M
  • Volume5100
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-35.90500M
  • Revenue TTM42.69M
  • Revenue Per Share TTM2.10
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.87

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -196.28500M 14.21M -100.09800M -212.93300M 6.55M
Minority interest - - - - -
Net income -196.29500M 14.19M -100.11800M -208.23300M 5.88M
Selling general administrative 50.58M 65.86M 71.09M 30.57M 0.56M
Selling and marketing expenses - 0.16M 0.25M 0.76M 1.16M
Gross profit 6.75M -1.69000M 11.68M 9.35M 14.82M
Reconciled depreciation 9.32M 9.44M 8.82M 8.17M -
Ebit - 14.21M -148.01200M -210.57900M -7.86954M
Ebitda - 23.58M -96.92700M -202.40500M -1.68354M
Depreciation and amortization - 9.38M 51.09M 8.17M 6.19M
Non operating income net other - - - -44.84869M 3.75M
Operating income -76.47900M -25.60000M -148.01200M -78.09100M -1.68354M
Other operating expenses - 166.24M 169.35M 92.37M 1.68M
Interest expense 3.02M 3.17M 3.17M 2.35M 3.75M
Tax provision 0.01000M 0.01M 0.02M -4.70000M -
Interest income 0.32M 0.36M 0.33M 0.37M -
Net interest income -2.69500M 0.36M -2.83900M -1.98400M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.01M 0.02M -4.70000M 0.67M
Total revenue 22.77M 17.98M 21.34M 14.28M 21.15M
Total operating expenses 99.25M 146.58M 159.69M 87.44M 1.68M
Cost of revenue 16.02M 19.66M 9.65M 4.93M 6.32M
Total other income expense net -117.11100M 39.80M 47.91M -61.00800M 8.23M
Discontinued operations - - - - -
Net income from continuing ops -196.29500M 14.19M -100.11800M -49.26030M 2.51M
Net income applicable to common shares - - - -49.26030M 2.51M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 143.89M 401.07M 414.13M 431.01M 291.61M
Intangible assets 11.00M 120.99M 123.19M 125.38M -
Earning assets - - - - -
Other current assets 0.33M 9.78M 0.00200M 0.87M 0.09M
Total liab 102.93M 202.16M 314.71M 962.41M 11.04M
Total stockholder equity 40.96M 198.90M 99.42M -531.40000M 280.56M
Deferred long term liab - - - 0.00060M -
Other current liab 2.45M 16.40M 11.66M 13.45M 0.02M
Common stock - 0.01M 0.01M 0.00100M 275.56M
Capital stock 0.02M 0.01M 0.01M 0.00100M -
Retained earnings -841.79100M -645.49600M -663.68100M -563.56300M 2.51M
Other liab - - - - -
Good will 7.35M 119.69M 123.30M 123.30M -
Other assets - - - - -
Cash 0.23M 13.97M 37.24M 54.31M 0.92M
Cash and equivalents - - - - -
Total current liabilities 67.30M 62.09M 26.23M 26.68M 0.23M
Current deferred revenue - 2.27M 2.20M 4.83M -
Net debt 39.01M 51.62M -6.10400M -23.66900M -0.91701M
Short term debt - 37.60M 3.05M 3.01M -
Short long term debt 39.24M 37.60M - - -
Short long term debt total - 65.59M 31.14M 30.64M -
Other stockholder equity - 443.31M 763.09M 32.16M 2.49M
Property plant equipment - - - - -
Total current assets 19.79M 33.50M 37.24M 72.16M 1.01M
Long term investments - - - - -
Net tangible assets - - - 214.13M 280.56M
Short term investments - - - 291.80M -
Net receivables 10.05M 6.97M 5.23M 6.55M -
Long term debt - - - - -
Inventory 5.75M 5.31M 9.55M 3.85M -
Accounts payable 14.14M 5.81M 9.32M 5.39M 0.21M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 0.00900M -414.12800M - -
Additional paid in capital - - - - -
Common stock total equity - - - 272.93M 0.00087M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -43.38262M 2.51M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 26.93M 38.15M 39.77M 20.09M -0.40546M
Deferred long term asset charges - - - - -
Non current assets total 124.10M 367.56M 376.89M 358.85M 290.60M
Capital lease obligations 26.18M 27.98M 31.14M 30.64M -
Long term debt total - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -4.04800M -5.23600M -5.90300M -0.13750M -287.50000M
Change to liabilities - - - 3.18M 0.23M
Total cashflows from investing activities - - - 0.58M -286.84900M
Net borrowings - - - - -0.15000M
Total cash from financing activities 24.09M 119.84M 98.56M 102.01M 288.84M
Change to operating activities - - - - -
Net income -196.29500M 14.19M -100.11800M -208.23300M 5.88M
Change in cash -18.63900M -23.27400M -17.43700M 26.01M 0.89M
Begin period cash flow 28.80M 52.08M 69.51M 43.51M 0.02M
End period cash flow 10.16M 28.80M 52.08M 69.51M 0.92M
Total cash from operating activities -38.68500M -137.87600M -110.09600M -63.19300M -1.09783M
Issuance of capital stock 21.89M 36.52M 83.40M 102.53M -
Depreciation 9.32M 9.44M 8.82M 8.17M 6.19M
Other cashflows from investing activities - - - 0.72M 0.65M
Dividends paid - 39.07M - - -
Change to inventory -0.86500M -16.89100M -6.42200M -0.64300M -1.70800M
Change to account receivables -6.82700M -3.58400M -1.90900M 1.65M 0.13M
Sale purchase of stock - -0.13200M 0.00000M -0.25600M 6.49M
Other cashflows from financing activities - -2.37200M 20.16M 102.27M 119.25M
Change to netincome - - - 46.63M 0.00622M
Capital expenditures 4.05M 5.24M 6.20M 27.83M 31.57M
Change receivables - - - - -
Cash flows other operating - - - -1.73151M -3.84556M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -0.60231M 0.89M
Change in working capital 3.25M -17.97600M -11.08300M 3.60M 0.14M
Stock based compensation 15.02M 15.86M 40.01M 4.37M 3.67M
Other non cash items -94.46500M -159.38300M -46.36900M 137.37M -7.13022M
Free cash flow -42.73300M -143.11200M -116.29900M -91.02700M -32.67283M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
CELUW
Celularity Inc		 - -% 0.005 - - - -
NVO
Novo Nordisk A/S		 1.54 3.36% 47.42 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.63 0.35% 468.42 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.53 0.90% 618.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. The company operates through Cell Therapy, Degenerative Disease, and BioBanking segments. Its lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. In addition, the company is developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. Celularity Inc. produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is based in Florham Park, New Jersey.

Celularity Inc

170 Park Avenue, Florham Park, NJ, United States, 07932

Key Executives

Name Title Year Born
Dr. Robert Joseph Hariri M.D., Ph.D. Founder, CEO & Chairman 1959
Mr. John R. Haines Sr. EVP, GM & Chief Admin. Officer 1957
Mr. David C. Beers C.F.A., CFA Chief Financial Officer 1970
Dr. Bradley Glover Ph.D. Exec. VP & COO 1969
Mr. Tim Wilk Sr. VP of Technical Operations NA
Carlos Ramirez SVP of Investor Relations NA
Mr. Keary R. Dunn Esq. EVP, Gen. Counsel, Chief Legal Officer & Head of Bus. Devel. 1970
Ms. Beth Steinbrenner Exec. VP of HR NA
Dr. Stephen A. Brigido D.P.M. Pres of Degenerative Diseases 1976
Dr. Anne Jones Ph.D. Exec. VP & Chief Bus. Officer 1971

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.